Scarica l'app Stockscreener
5.80
8.23%
-0.52
Dopo l'orario di chiusura:
5.60
-0.20
-3.45%
Decoy Therapeutics Inc Borsa (DCOY) Ultime notizie
Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus
Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget
Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Decoy Therapeutics regains Nasdaq minimum bid price compliance - Investing.com
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split - TipRanks
Decoy Therapeutics regains compliance with Nasdaq minimum bid price requirement - MarketScreener
Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView
Decoy Therapeutics regains Nasdaq minimum bid compliance after reverse split - TradingView
DCOY: 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists - TradingView
Decoy Therapeutics 10-K: Net loss $12.52M, EPS $(129.10) - TradingView
Decoy Therapeutics (NASDAQ: DCOY) details AI antiviral platform, merger and reverse stock splits - Stock Titan
Decoy Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Total liabilities & shareholders' equities of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World
If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DCOY | US79400X6022 - marketscreener.com
Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard
Decoy Therapeutics Inc. Earnings and Revenue – GETTEX:FP11 - TradingView
Debt to equity ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to cash flow ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free cash flow per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Revenue per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net current asset value per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value to EBITDA ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-controlling/minority interest of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to book ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total operating expenses of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
CapEx per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total debt per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Debt to assets ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total common shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Discontinued operations of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc. Statistics – GETTEX:FP11 - TradingView
Gross profit of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Taxes of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Preferred dividends of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
After tax other income/expense of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Diluted net income available to common stockholders of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Pretax income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-operating income (total) of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Basic earnings per share (basic EPS) of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free float of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc. Revenue Breakdown – GETTEX:FP11 - TradingView
Number of employees of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics (DCOY) Partners with Quantori to Enhance Anti - GuruFocus
Decoy Therapeutics partners with Quantori on AI peptide platform - Investing.com
Decoy Therapeutics enters collaboration with Quantori - TipRanks
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform – NEWSnet Michigan - michigan.newsnetmedia.com
Google Cloud-funded AI aims up to 100-fold faster antiviral peptide design - Stock Titan
Decoy Therapeutics Inc. Revenue Breakdown – MUN:FP11 - TradingView
Decoy Therapeutics Inc. Earnings and Revenue – MUN:FP11 - TradingView
Free cash flow of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Total equity of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Total assets of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):